MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) 133% HIGHER; announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints.
Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
Cytokinetics Inc. (Nasdaq: CYTK) 44.2% HIGHER; surging on news Amgen Inc. (Nasdaq: AMGN) exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics' cardiac contractility program.
The...
Post new comment